Abstract:Abstract Introduction/Background Atopic dermatitis (AD) is a chronic inflammatory skin disease associated with burdensome symptoms and decreased quality of life.1 Upadacitinib, an oral Janus kinase inhibitor approved to treat moderate-to-severe AD, met all primary endpoints in multiple phase 3 clinical trials for patients with AD.2,3,4 However, clinical trial results may not necessarily reflect outcomes in a real-world setting. There is a need to complement clinical trial findings with real-world data, particularly patient-reported outcomes, which provide a unique perspective of the patient experience. Objective To evaluate the real-world patient-reported experience and effectiveness of upadacitinib in adults with moderate-to-severe AD. Methods The real-world, observational SCALE-UP (Surveying the Clinically Relevant Patient-Reported Outcomes and Long-Term Effectiveness of Upadacitinib in Atopic Dermatitis) study surveyed adults with moderate-to-severe AD participating in a patient support program (PSP) for upadacitinib in the United States. Eligible participants were aged ≥ 18 years, were prescribed and actively receiving upadacitinib for moderate-to-severe AD, and were enrolled in the upadacitinib PSP for 2–12 months. A one-time online survey was used to evaluate patients’ experience with upadacitinib, including the degree of itch improvement and skin clearance, the time to itch improvement and skin clearance, and satisfaction with these items. Results This cross-sectional analysis included data from 204 patients enrolled in the upadacitinib PSP. The mean (SD) patient age was 45.3 (16.5) years, and the mean (SD) age at AD diagnosis was 30.3 (23.1) years. More than half (70.1%) of patients were female. Upadacitinib treatment duration was 2–6 months for 50.5% of patients and > 6 and ≤ 12 months for 49.5% of patients. The starting upadacitinib dose was 15 mg for 94.6% of patients and 30 mg for 3.9% of patients; at the time of the survey, 79.4% of patients were receiving upadacitinib 15 mg, and 19.6% were receiving upadacitinib 30 mg. Topical corticosteroids were used by 36.8% of patients at the time of the survey. Patients self-reported skin tones (%) were pale white (9.8%), white (39.7%), light brown (23.5%), moderate brown (18.1%), dark brown (5.9%), and deeply pigmented/black (2.5%). After receiving upadacitinib, 94.6% of patients reported itch improvement (86.8% “Very much” or “Much” improved and 7.8% “Minimally” improved. Among patients reporting itch relief, 87.0% noticed itch improvement within 1 week, with 27.5% noticing improvement in ≤ 1 day, 37.8% noticing improvement in 2–3 days, and 21.8% noticing improvement in 4–7 days. Among patients reporting itch relief, the proportions who were “Extremely” or “Very” satisfied with the degree and speed of their itch improvement were 87.0% and 86.0%, respectively. Clearer skin was also reported by 90.7% of patients (81.4% “Very much” or “Much” clearer and 9.3% “Minimally” clearer) after initiating upadacitinib. Of these patients, 89.2% noticed clearer skin within 14 days, with 30.8% noticing clearer skin in ≤ 3 days, 36.8% noticing clearer skin in 4–7 days, and 21.6% noticing clearer skin in 8–14 days. Among patients reporting clearer skin, the proportions who were “Extremely” or "Very” satisfied with the degree and speed of skin clearance were 83.8% and 83.2%, respectively. Conclusions Patients with moderate-to-severe AD treated with upadacitinib in a real-world setting experienced rapid itch relief and improved skin clearance, and reported high levels of satisfaction with both the degree and time course of itch relief and skin clearance. Results were consistent with the overall efficacy dynamics observed in clinical trials evaluating upadacitinib for treating AD. These real-world data complement clinical trial findings and provide a deeper perspective of patients’ experience when using upadacitinib to manage their moderate-to-severe AD, which may help inform shared decision-making discussions between patients and healthcare providers.

644 - Effectiveness and safety of upadacitinib in adolescent and adult patients with atopic dermatitis: an interim analysis of week 20-32 data from a real-world multicenter retrospective review

645 - Effectiveness and safety of upadacitinib in adolescent and adult patients with atopic dermatitis: an analysis of long-term (week 52) data from a real-world multicenter retrospective review

502 - Efficacy and safety of upadacitinib through 140 weeks in adolescents and adults with moderate-to-severe atopic dermatitis: phase 3 randomized clinical trial results

498 - Real-world use and effectiveness of upadacitinib in adults and adolescents with atopic dermatitis: preliminary analysis of the real-world multicountry AD-VISE study

409 Efficacy and safety of upadacitinib in adults and adolescents with moderate-to-severe atopic dermatitis: subgroup analysis of the Measure Up 1, Measure Up 2 and AD Up phase 3 clinical trials at 52 weeks

525 - Real-world effectiveness of upadacitinib in moderate-to-severe atopic dermatitis (AD): Results from cross-sectional analyses of the CorEvitas AD Registry

Efficacy and Safety of Upadacitinib vs Dupilumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: Week 16 results of an Open-label, Randomized, Efficacy Assessor-Blinded Head-to-Head Phase 3b/4 Study (Level Up)

527 - Efficacy of upadacitinib for moderate-to-severe atopic dermatitis: analysis of time spent in skin clearance response states from the Measure Up 1, Measure Up 2, and Heads Up studies

706 - Real-world patient experience of upadacitinib-treated adults with atopic dermatitis: results from the SCALE-UP study

The efficacy and safety of upadacitinib treatment for moderate to severe atopic dermatitis in real‐world practice in Japan

528 - Rapid skin clearance and itch improvement with upadacitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: results from a phase 3b head-to-head clinical trial (Heads Up)

Long-term Effectiveness and Safety of Upadacitinib for Atopic Dermatitis in a Real-world Setting: An Interim Analysis Through 48 Weeks of Observation

Upadacitinib treatment in a real‐world difficult‐to‐treat atopic dermatitis patient cohort

Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis

Effectiveness and safety of upadacitinib in patients with face and neck atopic dermatitis unresponsive to dupilumab

Efficacy and Safety of Upadacitinib in Patients with Psoriatic Arthritis: 2-Year Results from the Phase 3 SELECT-PsA 1 Study

533 - Long-term 5-year safety of upadacitinib in moderate-to-severe atopic dermatitis: an integrated analysis including over 7000 patient-years of exposure

Efficacy and Safety of Upadacitinib Treatment in Adolescents With Moderate-to-Severe Atopic Dermatitis

Treatment with Upadacitinib in Active Psoriatic Arthritis: Efficacy and Safety Data of the First 192 Patients from the UPJOINT Study, a Multicentre, Observational Study in Clinical Practice

32333 Clinical and Pharmacokinetic Results of Upadacitinib in Chinese Healthy Subjects and Subjects with Moderate-to-severe Atopic Dermatitis

Efficacy and safety of upadacitinib in the treatment of moderate-to-severe atopic dermatitis in adolescents: A systematic review and meta-analysis of randomized controlled trials